{
    "code": "60000999",
    "url": "https:\/\/info.fda.gov.tw\/MLMS\/H0001D.aspx?Type=Lic&LicId=60000999",
    "time": "2021-11-05 03:34:01",
    "許可證字號": "衛部菌疫輸字第000999號",
    "註銷狀態": "",
    "註銷日期": "",
    "註銷理由": "",
    "製造許可登錄編號": "",
    "有效日期": "114\/12\/24",
    "發證日期": "104\/12\/24",
    "許可證種類": "菌　疫",
    "舊證字號": "",
    "醫療器材級數": "",
    "第一等級醫療器材原登錄字號": "",
    "第一等級醫療器材新登錄字號": "",
    "通關簽審文件編號": "DHA06000099908",
    "中文品名": "欣銳擇 注射劑",
    "英文品名": "CYRAMZA injection",
    "適應症": "1.胃癌：\r\n(1)Ramucirumab併用paclitaxel適用於治療正接受或接受過fluoropyrimidine和platinum化學治療仍疾病惡化之晚期或轉移性胃腺癌(或胃食道接合處腺癌)。\r\n(2)Ramucirumab單一藥物適用於治療正接受或接受過fluoropyrimidine或platinum化學治療仍疾病惡化，且不適合接受含paclitaxel藥物治療之晚期或轉移性胃腺癌(或胃食道接合處腺癌)。\r\n2.非小細胞肺癌 (NSCLC):\r\n(1)Ramucirumab併用erlotinib適用於第一線治療具有表皮生長因子受體(EGFR) 突變之轉移性非小細胞肺癌。\r\n(2)Ramucirumab併用docetaxel適用於治療正接受或接受過含platinum化學治療仍疾病惡化之局部晚期或轉移性非小細胞肺癌。 \r\n3.大腸直腸癌: Ramucirumab併用FOLFIRI (irinotecan、葉酸及5-fluorouracil)適用於治療正接受或接受過bevacizumab、oxaliplatin及fluoropyrimidine治療仍疾病惡化之轉移性大腸直腸癌(mCRC)。 \r\n4.肝細胞癌(HCC): Ramucirumab單一療法適用於接受過sorafenib治療且alpha-fetoprotein(AFP) ≥400 ng\/mL之肝細胞癌病人。",
    "劑型": "270注射劑",
    "包裝": "100毫克，500毫克玻璃小瓶裝 各100支以下盒裝",
    "儲存溫度": "",
    "有效期間": "",
    "指示藥品審查基準": "",
    "標籤、仿單及包裝加註": "",
    "藥品類別": "06須由醫師處方使用",
    "管制藥品分類級別": "",
    "藥品分類": "",
    "監視期限": "109\/12\/24",
    "主成分略述": "Ramucirumab",
    "限制項目": "02輸　入 51免除銜接性臨床試驗",
    "申請商名稱": "1411301100  台灣禮來股份有限公司",
    "申請商地址": "台北市復興北路３６５號１１樓",
    "主製造廠": [
        {
            "": "UNITED STATES",
            "製程": ""
        }
    ],
    "次製造廠": [
        {
            "製造廠名稱": "FIE0009000  Eli Lilly Kinsale Limited",
            "製造廠廠址": "DUNDERROW, KINSALE COUNTRY CORK.",
            "製造廠公司地址": "",
            "製造廠國別": "IRELAND",
            "製程": "原料藥製造廠"
        },
        {
            "製造廠名稱": "FUS0665000  IMCLONE SYSTEM CORPORATION",
            "製造廠廠址": "IMCLONE DRIVE, BRANCHBURG, NJ 08876 USA",
            "製造廠公司地址": "",
            "製造廠國別": "UNITED STATES",
            "製程": "原料藥製造廠"
        }
    ],
    "CCC號列": "",
    "藥理治療分類": "",
    "ingredients": [
        {
            "成分類別": "主成分",
            "成分代碼": "1013005500",
            "成分名稱": "Ramucirumab",
            "含量描述": "",
            "含量": "10.0000000000",
            "單位": "MG\/ML"
        }
    ],
    "藥物辨識詳細資料": {
        "外觀尺寸": "",
        "特殊劑型": "",
        "顏色": "",
        "特殊氣味": "",
        "刻痕": "",
        "形狀": "",
        "標記一": "",
        "標記二": ""
    },
    "藥物辨識外觀圖片": [
        {
            "title": "Cyramza 100mg-vial-108-03-26(廠商自行上傳).pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=60000999&Seq=004&Type=10"
        },
        {
            "title": "Cyramza 500mg-Vial-108-03-26(廠商自行上傳).pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=60000999&Seq=003&Type=10"
        }
    ],
    "仿單外盒": [
        {
            "title": "Cyramza-Proposed truth-v2-CYR-0015-USPI-20200601+NSCLC NI-TFDA 20210521_Final-110-09-07.pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=60000999&Seq=009&Type=9"
        },
        {
            "title": "Cyramza 100mg-carton-108-03-26(廠商自行上傳).pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=60000999&Seq=007&Type=8"
        },
        {
            "title": "Cyramza 500mg-carton-108-03-26(廠商自行上傳).pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=60000999&Seq=006&Type=8"
        },
        {
            "title": "020009990005 100 carton-105-01-19.pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=60000999&Seq=003&Type=8"
        }
    ]
}